Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

EHA 2021 | CAR-NK: improved CRS and promising safety profiles in myeloma

Leo Rasche • 14 Jun 2021
EHA 2021
Multiple Myeloma CAR-NK

Leo Rasche, MD, University of Arkansas for Medical Sciences, Little Rock, AR, shares an update on chimeric antigen receptor natural killer cell (CAR-NK) therapy for multiple myeloma, highlighting reduced incidences of cytokine release syndrome (CRS) and promising tolerability profiles. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.

More from Leo Rasche

Novel targets in multiple myeloma & the role of the immune system in disease progression 9:26
Novel targets in multiple myeloma & the role of the immune system in disease progression
Arun Wiita et al. • 12 Apr 2025
Using spatial transcriptomics to study focal lesions in multiple myeloma 4:06
Using spatial transcriptomics to study focal lesions in multiple myeloma
Leo Rasche • 30 Jan 2025
Evolving treatment options in NDMM: transplant-eligible and transplant-ineligible patients 2:18
Evolving treatment options in NDMM: transplant-eligible and transplant-ineligible patients
Leo Rasche • 28 Sep 2023
WGS reveals sequential & persistent loss of BCMA and GPRC5D after bispecific antibodies in myeloma 1:47
WGS reveals sequential & persistent loss of BCMA and GPRC5D after bispecific antibodies in myeloma
Leo Rasche • 28 Sep 2023

Related Videos

The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial 10:22
The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial
Peter Voorhees • 19 Nov 2025
Promising approaches being explored in high-risk myeloma & trials to look out for 2:11
Promising approaches being explored in high-risk myeloma & trials to look out for
Sham Mailankody • 24 Oct 2025
The value of extensive profiling in single-arm trials for high-risk myeloma 2:39
The value of extensive profiling in single-arm trials for high-risk myeloma
Martin Kaiser • 24 Oct 2025
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy? 2:35
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy?
Sham Mailankody • 24 Oct 2025
The content of VJHemOnc is intended for healthcare professionals